pde9 inhibitor

PDE-9 inhibitor is used for treatment neurodegenerative diseases.

PDE9-IN-1 is a selective and orally bioavailable Inhibitor of PDE9A(IC50 of 8.7 nM).

PDE9-IN-(S)-C33 ((S)-C33) is a potent and selective inhibitor of PDE9 (IC50 = 11 nM). PDE9-IN-(S)-C33 can be used for central nervous system diseases and diabetes research.

PDE9-IN-2 (compound 6) is a PDE9 inhibitor that enhances heart failure management.

IMR687 is a PDE9 inhibitor that slows or stops the hydrolysis of cGMP. IMR687 can be regarded as a highly promising drug against Alzheimer's for improving memory.

Irsenontrine (E2027) is a selective and orally active inhibitor of phosphodiesterase 9 (PDE9), primarily used for researching neurological diseases.

Irsenontrine (E2027) maleate is a selective and orally active inhibitor of phosphodiesterase 9 (PDE9). It can be utilized in the study of neurological diseases.

(R)-Irsenontrine ((R)-E2027), the R-enantiomer of Irsenontrine, is a potent inhibitor of phosphodiesterase 9 (PDE9) with an IC50 of 0.041 μM, primarily used in neurological disease research [1].

Tovinontrine (IMR-687) (IMR-687) is a potent and selective inhibitor of phosphodiesterase-9 (PDE9), designed to target sickle cell disease treatment. It exhibits high efficacy, with IC 50 values of 8.19 nM and 9.99 nM for PDE9A1 and PDE9A2, respectively [1].

PDE11A4-IN-1 (compound 23b) is a potent, selective inhibitor of PDE11A4 with an IC50 of 12 nM, demonstrating high selectivity against PDE1, PDE2, PDE7, PDE8, and PDE9 [1].